temuterkib   Click here for help

GtoPdb Ligand ID: 9975

Synonyms: LY-3214996 | LY3214996
PDB Ligand
Compound class: Synthetic organic
Comment: LY3214996 is an ERK1/2 inhibitor that is in early stage clinical development for the potential treatment of advanced non-hematological tumours, in particular for malignancies carrying activating MAPK pathway alterations, and which are refractory to RAF and MEK inhibitors.
(Note: ERK1= MAPK3, ERK2= MAPK1). The chemical structure of LY3214996 matches that for the INN compound temuterkib that was surfaced in WHO Proposed list 125 in July 2021.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 116.65
Molecular weight 453.19
XLogP 0.69
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1c2cc(sc2C(N1CCN1CCOCC1)(C)C)c1ccnc(n1)Nc1ccnn1C
Isomeric SMILES O=C1c2cc(sc2C(N1CCN1CCOCC1)(C)C)c1ccnc(n1)Nc1ccnn1C
InChI InChI=1S/C22H27N7O2S/c1-22(2)19-15(20(30)29(22)9-8-28-10-12-31-13-11-28)14-17(32-19)16-4-6-23-21(25-16)26-18-5-7-24-27(18)3/h4-7,14H,8-13H2,1-3H3,(H,23,25,26)
InChI Key JNPRPMBJODOFEC-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Preliminary proof of efficacy of LY3214996 is being evaluated in Phase 1 clinical study NCT02857270.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02857270 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1 Interventional Eli Lilly and Company